Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Recruiting 56Active not recruiting 40Not yet recruiting 8Terminated 5Suspended 3Completed 3Withdrawn 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

Specimen Handling 25Magnetic Resonance Spectroscopy 17Biopsy 15Cyclophosphamide 6venetoclax 5Vincristine 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Azacitidine 4pembrolizumab 3fludarabine phosphate 3X-Rays 3Taxes 3Radiation 3Injections 3Cetuximab 3trastuzumab deruxtecan 2fludarabine 2decitabine and cedazuridine drug combination 2cemiplimab 2Tacrolimus 2Standard of Care 2Sirolimus 2Radiotherapy 2Radiosurgery 2Prednisone 2Practice Guidelines as Topic 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × X-Rays × 90 days × Clear all
NCT04539366 2026-05-13

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

National Cancer Institute (NCI)

Phase 1 Suspended
67 enrolled
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡